MedGenome has taken a majority stake in Gujarat-based Green Cross Genetics Lab, a pathology chain with over three decades of operation. This move expands MedGenome's diagnostic network into western India, where it now controls 17 laboratories and 35 collection centers. The partnership fuses traditional pathology with advanced genomics to reach more patients in underserved areas.
Established Network Meets Cutting-Edge Genomics
Green Cross, founded by Vinod Patel, has built a reputation for reliable diagnostics across Gujarat. Its 17 labs and 35 collection points serve patients through a team of more than 500 professionals, offering over 800 tests under expert oversight. MedGenome brings South Asia's largest CAP-accredited multiomics facility, powered by AI and machine learning for precise genetic analysis.
Dr. Vedam Ramprasad, MedGenome's CEO, described the deal as a way to strengthen presence in Gujarat and extend affordable omics solutions to Tier 2 and Tier 3 cities. He emphasized the alignment with Green Cross's legacy of trust, aiming to advance early disease detection through genomics. Patel, Green Cross's promoter and director, noted the synergy of their infrastructure and expertise with MedGenome's genomic platform to expand service offerings nationwide.
Broadening Access to Precision Diagnostics
The collaboration integrates genomics into routine pathology, providing clinicians with actionable genetic insights for complex diseases. Green Cross's extensive reach in Gujarat complements MedGenome's technological edge, creating a hybrid model that bridges urban and rural healthcare gaps. This approach addresses India's growing demand for personalized medicine, where genetic testing can guide treatments for conditions like cancer and rare disorders.
Implications for India's Healthcare Landscape
India's diagnostics sector faces challenges from uneven access and rising chronic disease burdens, with genomics offering tools for prevention and targeted therapies. By embedding genetic capabilities into established lab chains, MedGenome and Green Cross position precision healthcare within reach of broader populations. The promoters of Green Cross will retain leadership, ensuring continuity as the business scales. This investment signals a trend toward consolidated networks that combine local trust with global innovation, potentially influencing similar expansions across other regions.
